Protective roles of mesenchymal stem cells on skin photoaging: A narrative review

Huang

Photoderm Photoimm Photomed

et al. 2022

Background Mesenchymal stem cells‐derived exosome (MSCs‐exo) was identified to reduce photoaging. The purpose of this study was to investigate the potential role of microRNA (miR)‐29b‐3p derived from bone marrow MSCs‐exo (BMSCs‐exo) in photoaging. Methods Exosomes were isolated from BMSCs and verified by Western blot. A photoaging cell model was constructed by UVB irradiation of human dermal fibroblasts (HDFs). Quantitative real‐time PCR (RT‐qPCR) was performed to detect the mRNA levels of miR‐29b‐3p, collagen type I and matrix metalloproteinases (MMPs). CCK‐8, Transwell and flow cytometry were applicated to examine cell viability, migration and apoptosis. Commercial kits are used to measure levels of oxidative stress indicators. Finally, a dual‐luciferase reporter assay was applied to validate the target of miR‐29b‐3p. Results Extracted exosomes were positive for HSP70 and CD9. Survival of HDFs increased in an exosome concentration‐dependent manner. UVB irradiation inhibited miR‐29b‐3p levels compared with controls, but BMSCs‐exo treatment restored miR‐29b‐3p levels (p < .05). Additionally, BMSCs‐exo‐miR‐29b‐3p reversed the inhibition of HDFs migration and oxidative stress by UVB irradiation, as well as the promotion of apoptosis. However, this reversal was attenuated by the suppression of miR‐29b‐3p (p < .05). Furthermore, BMSCs‐exo‐miR‐29b‐3p also inhibited the degradation of collagen type I and the production of MMPs in photoaging, and they were also eliminated by the reduced miR‐29b‐3p. Finally, MMP‐2 was the target gene of miR‐29b‐3p. Conclusion Our study presented a novel role for BMSCs‐exo‐miR‐29b‐3p in improving skin photoaging function, and these findings may provide new insights into the targeted treatment of skin photoaging.

mentioning

confidence: 97%

Bone marrow mesenchymal stem cell‐derived exosome miR‐29b‐3p alleviates UV irradiation‐induced photoaging in skin fibroblast

Huang

Photoderm Photoimm Photomed

et al. 2022

“…Recent studies also suggested that MSCs stimulated human dermal fibroblasts via paracrine effects and enhanced cutaneous wound healing. [ 24,25 ] The effect of UCMSC‐NV on HUVEC tube‐formation also revealed that UCMSC‐NV promoted angiogenesis, suggesting that UCMSC‐NV may affect wound healing by promoting fibroblast migration and angiogenesis.…”

Section: Discussionmentioning

confidence: 99%

Umbilical cord mesenchymal‐stem‐cell‐derived nanovesicles as a novel strategy to promote wound healing in diabetes

Zhao

Chen³

et al. 2023

Nano Select

Objective Recent studies found that exosomes (Exo) derived from mesenchymal stem cells (MSC) (MSC‐Exo) accelerated diabetic wound healing. However, the low yield during exosome extraction is still a major barrier to their clinical utility. Methods We constructed a method to produce umbilical cord MSC‐derived nanovesicles (UCMSC‐NV) by serial extrusion through filters and investigated the effects of UCMSC‐NV on wound healing in vivo and in vitro, as well as the potential mechanisms. Results We found that the characteristics of UCMSC‐NV were similar to those of exsome (UCMSC‐Exo) but with much higher production yields. Further analysis showed that UCMSC‐NV promoted the migration of fibroblasts and angiogenesis in vitro, and both UCMSC‐NV and UCMSC‐Exo showed similar therapeutic capacities for wound healing in vivo. Sequencing analysis revealed that UCMSC‐NV and UCMSC‐Exo had similar miRNA compositions, and the target genes of the differentially expressed miRNAs in UCMSC‐NV were enriched in pathways of inflammation and damage‐repair‐related functions. Mass spectrometry analysis showed that UCMSC‐NV encapsulated functional proteins that may achieve therapeutic effect equally as good as UCMSC‐Exo. Conclusions UCMSC‐NV are more efficacious and can be obtained at a higher yield than UCMSC‐Exo and are a promising therapeutic strategy to improve wound healing in diabetes patients.

“…Stem cells prevail in several tissues and have the potential to differentiate, and hence can be exploited for DFU treatment. 80 Table 1 presents details on the different types of current DFU therapies approved by the Food and Drug Administration (FDA).…”

Section: Current Therapies For Diabetic Foot Ulcersmentioning

confidence: 99%

A review on contemporary nanomaterial-based therapeutics for the treatment of diabetic foot ulcers (DFUs) with special reference to the Indian scenario

et al. 2022